Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Karyopharm therapeutics inc. save search
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2023-12-06 (Crawled : 09:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 0.81%
H: 8.51%
C: 3.74%
xpovio approval treatment
Global Glioma Treatment Market Research Report 2023: Breakthrough Oncolytic Virus Therapy Offers New Hope for Glioma Patients - Forecast to 2027 and 2032
Published: 2023-11-27 (Crawled : 23:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 4.0%
H: 1.93%
C: -7.72%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.03%
H: 0.85%
C: 0.44%
report hope treatment research global virus therapy market
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
Published: 2023-07-17 (Crawled : 20:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 18.95%
H: 0.0%
C: -18.13%
fda treatment designation fast track designation
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2023-07-17 (Crawled : 01:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -1.28%
H: 4.55%
C: -0.65%
xpovio approval treatment
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2023-06-01 (Crawled : 11:00) - biospace.com/
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 0.44%
H: 0.44%
C: -3.08%
xpovio australia treatment plus
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Published: 2023-02-21 (Crawled : 15:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -1.41%
H: 1.14%
C: -8.57%
nexpovio treatment one authorization therapy group
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
Published: 2022-10-31 (Crawled : 21:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 1.47%
H: 2.07%
C: -2.48%
treatment designation group
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-07-20 (Crawled : 12:00) - biospace.com/
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 3.84%
H: 7.7%
C: -0.82%
treatment granted
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
Published: 2022-05-23 (Crawled : 03:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -1.35%
H: 2.56%
C: -0.34%
xpovio treatment lymphomas
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
Published: 2022-05-20 (Crawled : 13:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 6.65%
H: 0.0%
C: 0.0%
nexpovio treatment chmp positive group
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
Published: 2022-05-18 (Crawled : 07:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -2.32%
H: 2.01%
C: -1.28%
xpovio guidelines treatment management china diagnostic
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
Published: 2022-05-16 (Crawled : 03:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 1.52%
H: 8.99%
C: 2.25%
xpovio treatment commercial china
Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines
Published: 2022-05-13 (Crawled : 01:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 2.94%
H: 0.0%
C: 0.0%
xpovio guidelines treatment
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Published: 2022-03-02 (Crawled : 01:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -28.03%
H: 1.74%
C: -16.2%
xpovio treatment approval cel t-cell
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 1.39%
H: 6.65%
C: 6.09%
treatment fda drug orphan drug syndros designation
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
Published: 2021-12-30 (Crawled : 03:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -0.59%
H: 4.48%
C: 0.3%
atg-016 treatment solid tumors
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
Published: 2021-12-17 (Crawled : 15:30) - biospace.com/
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -2.37%
H: 0.0%
C: 0.0%
xpovio treatment approval china
Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-12-17 (Crawled : 14:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -2.37%
H: 0.0%
C: 0.0%
xpovio treatment approval china
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
Published: 2021-08-24 (Crawled : 01:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 1.55%
H: 0.09%
C: -3.62%
treatment fibrosis china approval
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
Published: 2021-07-14 (Crawled : 02:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 0.32%
H: 0.21%
C: -5.12%
new drug treatment drug application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.